Ablation of Src Family Kinases FGR in hosts reduces confers response of high-grade ovarian cancer to immune checkpoint blockade treatment

被引：0
|
作者：
Ernst, M. [1 ]
Poh, A. [2 ]
Christie, E. [3 ]
机构：
[1] Olivia Newton John Canc Res Inst, Canc & Inflammat, Heidelberg, Vic, Australia
[2] Olivia Newton John Canc Res Inst, Canc Inflammat Lab, Heidelberg, Vic, Australia
[3] Peter MacCallum Canc Ctr, Canc Evolut & Metastasis Program, Melbourne, Vic, Australia
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114984
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB-506
引用
收藏
页码：S180 / S180
页数：1
相关论文
共 43 条
  • [41] Use of Gynecologic Cancer Intergroup (GCIG) CA125 criteria to evaluate cell cycle checkpoint kinase 1 inhibitor (CHK1i) prexasertib response and disease progression (PD) in recurrent high-grade serous ovarian cancer (HGSOC)
    Ibanez, Kristen
    Donohue, Duncan
    Malys, Tyler
    Lee, Jung-Min
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] PROM1, CXCL8, RUNX1, NAV1 and TP73 genes as independent markers predictive of prognosis or response to treatment in two cohorts of high-grade serous ovarian cancer patients
    Dansonka-Mieszkowska, Agnieszka
    Szafron, Laura Aleksandra
    Kulesza, Magdalena
    Stachurska, Anna
    Leszczynski, Pawel
    Tomczyk-Szatkowska, Agnieszka
    Sobiczewski, Piotr
    Parada, Joanna
    Kulinczak, Mariusz
    Moes-Sosnowska, Joanna
    Pienkowska-Grela, Barbara
    Kupryjanczyk, Jolanta
    Chechlinska, Magdalena
    Szafron, Lukasz Michal
    PLOS ONE, 2022, 17 (07):
  • [43] The role of innate immune system in modulating CHK1 inhibitor (CHK1i) response in BRCA wild-type (BRCAwt), platinum-resistant high-grade serous ovarian cancer (PR-HGSOC): Exploratory analysis from a phase II study of CHK1i prexasertib
    Giudice, Elena
    Nair, Jayakumar
    Huang, Tzu-Ting
    Lee, Min-Jung
    Trepel, Jane B.
    Lee, Jung-Min
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345